Lutetium (177Lu) Zadavotide Quraxetan is a small molecule commercialized by Lantheus, with a leading Phase III program in Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Lutetium (177Lu) Zadavotide Quraxetan’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Lutetium (177Lu) Zadavotide Quraxetan is expected to reach an annual total of $921 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Lutetium (177Lu) Zadavotide Quraxetan Overview
Lutetium (177Lu) zadavotide guraxetan (PNT-2002) is under development for the treatment of metastatic castration resistant prostate cancer, metastatic clear cell renal cell carcinoma (RCC) and oligorecurrent prostate cancer. It is administered through intravenous route. The drug candidate consists of PSMA ligand conjugated with lutetium 177 and acts by targeting cells expressing PSMA. It is being developed based on canSEEK technology.
Lantheus Overview
Lantheus is a radiopharmaceutical company that specializes in the development and distribution of precision diagnostic and therapeutic products. The company’s products include Pylarify, Definity, TechneLite, aBSI, aPROMISE, Cardiolite, NEUROLITE, and Xenon Xe-133 Gas. Lantheus products applications in the therapeutic areas of oncology, urology, nuclear medicine, cardiology, sonography and radiology among others. It serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacy and clinics. The company has operations in Canada, Sweden, Ireland, the UK and the US. Lantheus is headquartered in Bedford, Massachusetts, the US.
The company reported revenues of (US Dollars) US$1,296.4 million for the fiscal year ended December 2023 (FY2023), an increase of 38.6% over FY2022. In FY2023, the company’s operating margin was 28.1%, compared to an operating margin of 3.8% in FY2022. In FY2023, the company recorded a net margin of 25.2%, compared to a net margin of 3% in FY2022.
The company reported revenues of US$394.1 million for the second quarter ended June 2024, an increase of 6.5% over the previous quarter.
For a complete picture of Lutetium (177Lu) Zadavotide Quraxetan’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
